NCT00407511

Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP

A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.

Conditions

• Diabetic Peripheral Neuropathic Pain (DPN)
• Postherpetic Neuralgia (PHN)
• HIV-related Neuropathic Pain (HIV)
• Chemotherapy Induced Neuropathic Pain

Interventions

Type	Name	Description
DRUG	Pregabalin	Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).

Timeline

• Start date: 2007-01-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2006-12-05
• Last updated: 2021-02-09
• Results posted: 2009-08-19

Locations

11 sites across 5 countries: Colombia, Ecuador, Mexico, Peru, Venezuela